Muhdo Health, a DNA and epigenetic testing company, has signed an exclusive distribution agreement with Rgentic Saglik Turizm ve Ticaret AS (Rgnetic) to bring genetic testing kits to Turkey.
Muhdo Health is enhancing the customer experience by translating its app into Turkish. This update allows local users to access their results on mobile devices.
The web-based Practitioner Portal will also be available in Turkish, enabling local clinics to provide consultations in the native language.
To support the partnership, Rgentic will launch a dedicated Turkish-language website. The site will offer both DNA and Epigenetic tests to consumers and clinics in Turkey.
This collaboration will help Muhdo Health expand its presence in Turkey’s health and longevity sector.
Muhdo Health CEO Nathan Berkley said: “Increasing the exposure of the Muhdo brand in Turkey and partnering with a trusted entity with robust commercial connections will propel our business forward.
“This exclusive partnership enables Muhdo to reach a new audience in a territory renowned for health, wellbeing, and longevity.”
Rgentic specialises in medical services, particularly in aesthetic and plastic surgery, cosmetic dentistry, and bariatric surgery. The company aims to provide proper medical standards, short waiting times, and transparent, cost-effective pricing.
Rgentic Director Tekin Aldemir said: “As Rgentic, we are very excited to partner with Muhdo and provide our clients and partners with the best genetic and epigenetic testing solutions on the market.
“We also look forward to expanding this partnership in the near future beyond Turkey, leveraging our existing network in the neighbouring territories of Turkey.”
Muhdo Health is said to be the world’s first company to offer internal wellness epigenetic profiling directly to companies and consumers.
The next-generation genetic and big data company aims to envision the mass personalisation of preventive and curative health through epigenetics and analytics.
In a similar development, in November last year, US-based healthcare company WellRX acquired Bioreach, a laboratory specialising in advanced bloodwork and genetic testing.
